Weiss Multi-Strategy Advisers’s Axsome Therapeutics AXSM Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,000	Closed	-$290K	–	656
2022 Q1	$290K	Sell	7,000 -7,139	-50%	-$221K	0.01%	607
2021 Q4	$534K	Sell	14,139 -3,127	-18%	-$115K	0.01%	545
2021 Q3	$569K	Buy	17,266 +4,251	+33%	+$166K	0.01%	541
2021 Q2	$878K	Buy	13,015 +465	+4%	+$27.9K	0.02%	504
2021 Q1	$711K	Sell	12,550 -513	-4%	-$36.1K	0.02%	521
2020 Q4	$1.06M	Buy	13,063 +3,063	+31%	+$229K	0.02%	482
2020 Q3	$713K	Buy	10,000 +5,000	+100%	+$390K	0.02%	453
2020 Q2	$411K	Buy	+5,000	New	+$385K	0.01%	479

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Weiss Multi-Strategy Advisers's AXSM Position: Q2 2022 in Review

Weiss Multi-Strategy Advisers sold out of Axsome Therapeutics (AXSM) in Q2 2022, closing a stake of 7,000 shares — an estimated $290K sold.

Weiss Multi-Strategy Advisers first reported a position in AXSM in Q2 2020 and held it in 8 quarters. The position peaked at $1.06M in Q4 2020. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

Weiss Multi-Strategy Advisers reported no remaining Axsome Therapeutics position as of Q2 2022 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 7,000 Axsome Therapeutics shares in Q2 2022, an estimated $290K.
Weiss Multi-Strategy Advisers first reported a position in Axsome Therapeutics in Q2 2020 and held it in 8 quarters.
Weiss Multi-Strategy Advisers's Axsome Therapeutics position peaked at $1.06M in Q4 2020.
174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.